SYDNEY, Jan. 14, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has closed its ...
Kazia Therapeutics (KZIA) announced that it has entered into a definitive agreement for the purchase and sale of up to an aggregate of 1,333,333 of the company’s American Depositary Shares, each ...
Kazia Therapeutics Limited (NASDAQ:KZIA) stock is trading lower on Tuesday after the company provided a regulatory update on paxalisib for glioblastoma (GBM) following its Type C clinical meeting with ...
Kazia Therapeutics (Nasdaq: KZIA), an oncology-focused Australian drug developer, has been advised by the US Food and Drug Administration that accelerated approval for its brain cancer drug, paxalisib ...
SYDNEY - Kazia Therapeutics Limited (NASDAQ: KZIA), a small-cap biotech company ($13.5M market cap) specializing in oncology drug development, has recently concluded discussions with the U.S. Food and ...
1 Day KZIA -41.61% DJIA -0.19% Russell 2K -0.03% Health Care/Life Sciences -0.90% ...
Kazia Therapeutics stock retreated Tuesday after the FDA said it could consider standard, but not accelerated, approval for the company's brain cancer drug. Shares of the oncology-focused drug ...
SYDNEY, Dec. 31, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today provided a regulatory update on paxalisib for the treatment of ...
Kazia plans to outline a regulatory and clinical path forward for paxalisib by January 2025. Get Wall Street's Hottest Chart Every Morning Kazia Therapeutics Limited KZIA stock is trading lower on ...
Kazia Therapeutics Limited (NASDAQ:KZIA) stock is trading lower on Tuesday after the company provided a regulatory update on paxalisib for glioblastoma (GBM) following its Type C clinical meeting with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback